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Previous evaluations of themolecularGenoType tests have promoted their use to detect resistance to first- and second-line antituber-
culosis drugs in different geographical regions.However, there are known geographic variations in themutations associatedwith drug
resistance inMycobacterium tuberculosis, and especially in SouthAmerica, there is a paucity of information regarding the frequencies
and types ofmutations associatedwith resistance to first- and second-line antituberculosis drugs.We therefore evaluated the perfor-
mance of theGenoType kits in this region by testing 228M. tuberculosis isolates inColombia, including 134 resistant and 94 pansus-
ceptible strains.Overall, the sensitivity and specificity of theGenoTypeMTBDRplus test ranged from92 to 96%and 97 to 100%, re-
spectively; the agreement indexwas optimal (Cohen’s kappa,>0.8). The sensitivity of theGenoTypeMTBDRsl test ranged from84 to
100%and the specificity from88 to 100%.Themost commonmutationswere katG S315T1, rpoB S531L, embBM306V, gyrAD94G,
and rrsA1401G.Our results reflect the utility of theGenoType tests inColombia; however, as somediscordance still exists between the
conventional andmolecular approaches in resistance testing, we adhere to the recommendation that theGenoType tests serve as early
guides for therapy, followed by phenotypic drug susceptibility testing for all cases.
In June 2008, the World Health Organization (WHO) endorsedthe use of rapid reverse line blot tests to detect multidrug-resis-
tant tuberculosis (MDR-TB) strains. This step was taken in order
to improve the timely detection ofMDR-TB, thereby reducing the
morbidity and mortality associated with this important public
health threat and facilitating efforts to stop the transmission of
such strains (1). One of the endorsed rapid molecular tests, the
GenoType, consists of two separate reverse line blot assays for detect-
ing mutations associated with drug resistance. The GenoType
MTBDRplus test is used to detect mutations associated with resis-
tance to rifampin and isoniazid, and the GenoTypeMTBDRsl test
detects mutations associated with resistance to ethambutol, fluo-
roquinolones, and second-line injectables.
Previous evaluations of the GenoType kits have documented
their performance in detecting resistance to first- and second-line
antituberculosis (anti-TB) drugs in different continents, like Af-
rica, Asia, and Europe (2, 3, 4, 5). From these studies, it became
clear that there are geographic variations in the mutations that are
associatedwith drug resistance inMycobacterium tuberculosis (6). Es-
pecially in South America, there is a paucity of information on the
distribution and types of gene mutations associated with drug resis-
tance (7).
Thus, given that theGenoTypeMTBDRplus andMTBDRsl assays
were recently introduced into use in the Latin American regions, our
goal was to determine and describe the frequency ofmutations asso-
ciated with drug resistance to first- and second-line anti-TB drugs in
Colombia and to complete a performance evaluationof the two tests.
MATERIALS AND METHODS
Study site. This study was conducted at the Centro Internacional de En-
trenamiento e InvestigacionesMédicas (CIDEIM) in Cali, Colombia. IRB
approval was obtained prior to the initiation of this study.
Clinical strains. Two hundred twenty-eight M. tuberculosis strains
were selected randomly from a collection of strains that were submitted to
or isolated at the CIDEIM to perform drug susceptibility testing between
2001 and 2011. These corresponded to a total of 94 pansusceptible strains
and a group of 134 resistant strains, composed of monoresistant, MDR, and
extensively drug-resistant (XDR) strains, including other resistant combina-
tions. The frozen strains were thawed and cultured on Löwenstein-Jensen
slants for genotypic evaluation. Themajority of the strainswere isolated from
patients who were diagnosed in the state of Valle del Cauca, Colombia.
Phenotypic drug susceptibility testing. Phenotypic drug susceptibil-
ity testing (DST), which is considered the gold standard in resistance
testing, was performed using the indirect agar proportion method (PM)
onMiddlebrook 7H10 agar (8), with the following antituberculosis drugs
and concentrations: 0.2 and 1 g/ml isoniazid (INH), 1 g/ml rifampin
(RIF), 5 g/ml ethambutol (EMB), 2 g/ml ciprofloxacin (CIP) and
moxifloxacin (MOX), and 5 g/ml amikacin (AMK) and kanamycin
(KAN). M. tuberculosis H37Rv and an XDR clinical strain were used as
controls for each group of DST that was processed.
GenoType MTBDRplus and GenoType MTBDRsl testing. The
GenoTypeMTBDRplus test (Hain Lifescience GmbH,Nehren, Germany)
detects INH and RIF resistance mutations in the katG, inhA, and rpoB
genes. The GenoType MTBDRsl test (Hain Lifescience GmbH, Nehren,
Germany) visualizes mutations in the gyrA, rrs, and embB genes that are
associated with resistance to fluoroquinolones, second-line injectables,
and EMB. The steps for both tests, including the DNA extraction step,
were performed according to the manufacturer’s instructions. DNA am-
plification was performed using HotStarTaq DNA polymerase (Qiagen,
GmbH, Hilden, Germany) with the recommended number of cycles. Fi-
nally, hybridization of the single-stranded biotin-labeled amplicons to
membrane-bound probes on the strips, followed by the addition of con-
jugate and substrate to generate visible hybridization patterns on the strip,
were performed using a TwinCubator (Hain Lifescience GmbH, Nehren,
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Germany). Strips were allowed to dry and were interpreted according to
the guide included in the kit. For each gene, the test evaluates the presence
of wild-type (WT) and/or mutant (MUT) sequences.
Statistical analysis. Laboratory data were processed and analyzed us-
ing SPSS version 20.0 statistical software (SPSS Inc., Chicago, IL). Sensi-
tivity, specificity, negative and positive predictive values, and concor-
dance were calculated applying the Web-based open-source program
OpenEpi, using a 95% confidence interval.
RESULTS
Performance of the GenoType MTBDRplus kit. GenoType
MTBDRplus correctly identified INH resistance in 125/132
strains, RIF resistance in 119/124 strains, andMDR-TB in 114/123
of the tested strains (Table 1). The test yielded 7 false-negative
results in INH-resistant strains; all 7 only revealed hybridization
toWT probes and showed nomutations on the resistance probes.
No false positives were found in this test. Most mutations (122/
125) associated with resistance to INH were observed in the katG
gene. Only 6% (8/125) of the INH-resistant strains revealed mu-
tations in the inhA gene. Moreover, 6 out of those 8 strains also
had an additional mutation in the katG gene, and thus, only two
strains had mutations exclusively in the inhA gene. The WT
probes for inhA were absent for one additional strain without
hybridization in the other MUT bands; this strain was also classi-
fied as INH resistant.
Regarding the identification of RIF resistance, the test detected
five false negatives, and all of them presented a WT pattern. Two
false-positivemolecular detections of RIF resistance came to light;
one of them was classified as resistant because of the absence of a
WT7 band yet noMUT bands, and the other strain had aMUT2B
(H526D) band. Overall, the test had good performance in the
detection of resistance to both INH and RIF and hence the detec-
tion ofMDR strains, with a sensitivity and specificity of92%and
96%, respectively. The concordance between the phenotypic and
molecular analyses amounted to nearly 0.90.
GenoTypeMTBDRsl performance. The GenoTypeMTBDRsl
test correctly detected 66/78 strains that were resistant to EMB,
15/17 to CIP, 3/3 to MOX, 27/29 to AMK, and 4/4 to KAN (Table
2). For EMB, the molecular test detected 12 false negatives, all of
which exclusively revealed WT bands and an absence of muta-
tions. In addition, two false-positive strains associated with the
embB gene were detected; these were classified as resistant since
they showed themutationsMUT1A-M306I andMUT1B-M306V.
Similarly, two false-negative results in the detection of CIP resis-
tance were observed, which were associated with an absence of
mutations in the gyrA gene, showing only WT bands.
Although eight strains were found to have a false-positive re-
sult to MOX, this observation should not be seen as a completely
negative feature of the test, as 7/8 of these strains were resistant to
CIP. Considering the current critical concentration for MOX, the
concordance of the test to detect resistance to MOX should be
given more consideration. Nevertheless, it remains important to
knowwhether the causative bacteria ofMDR-TB andXDR-TB are
still susceptible to at least one fluoroquinolone.
For second-line injectables, only two false-positive results were
detected for AMK, and there were no discordances for KAN.
Therefore, overall, the GenoTypeMTBDRsl test had good perfor-
mance in detecting resistance against EMB, fluoroquinolones, and
second-line injectables, with variable, but high, sensitivities and
specificities (between 84% and 100% and 88% and 100%, respec-
tively) and variable concordance (between 0.4 and 1).
Frequency of mutations. The most frequent mutations de-
tected by the GenoTypeMTBDRplus andMTDRsl tests are shown
in Table 3. Several less-common mutations were also found: for
rpoB, H526Y (n 11; 9%), D516V (n 9; 8%), and H526D (n
5; 4%), and for katG and inhA, S315T2 (n  12; 10%) and T8C
(n 2; 2%). Additionally, the D94A (20%; n 3), D94N/Y (13%;
n 2), and A90V (n 2; 13%)mutations were observed for gyrA,
TABLE 1 GenoType MTBDRplus performance with first-line antituberculosis drugs
GenoType
MTBDRplus result
Results of the
proportion method Sensitivitya Specificitya PPVa,b NPVa,c
Cohen’s
kappaa
Isoniazid (inhA and
katG)
94.7 (89.46–97.41) 100 (95.9–100) 100 (97.02–100) 92.78 (85.85–96.46) 0.935 (0.80–1)
Resistant Susceptible
Resistant 125 0
Susceptible 7 90
Rifampin (rpoB) 95.97 (90.91–98.27) 97.94 (92.79–99.43) 98.35 (94.17–99.55) 95 (88.82–97.85) 0.936 (0.80–1)
Resistant Susceptible
Resistant 119 2
Susceptible 5 95
MDR statusd 92.68 (86.68–96.1) 97.96 (92.86–99.44) 98.28 (93.93–99.53) 91.43 (84.51–95.43) 0.899 (0.76–1)
MDR Non-MDR
MDR 114 2
Non-MDR 9 96
a Data are reported as % (95% CI).
b PPV, positive predictive value.
c NPV, negative predictive value.
d MDR, multidrug-resistant.
Mutations and Tuberculosis Drug Resistance in Colombia
July 2013 Volume 51 Number 7 jcm.asm.org 2221
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
as well as the G1484T (4%; n 1) mutation for rrs and theM306I
(n 9, 14%) mutation for embB.
This study revealed the presence of 11 heteroresistant strains
(according to GenoType tests): one associated with katG hetero-
resistance, one associated with inhA, three associated with gyrA,
four with rrs, one with embB, and one case associated with both
inhA and rrs heteroresistance. This heteroresistance is evidenced
by the simultaneous hybridization of aWTprobe andMUTprobe
on a specific position of a gene.
Susceptibility or resistance in the absence of mutations.
Some strains did not show hybridization on any WT or MUT
probe (Table 4), a result that according tomanufacturer’s instruc-
tions classifies the strain as resistant. The majority of these cases
were RIF resistant, associated with the absence ofWT7 in the rpoB
gene (codons 526 to 529), MUT2A (H526Y), and MUT2B
(H526D). Five INH-resistant cases were associated with the ab-
sence of WT and MUT probes on the inhA gene: four on WT2
(position 8) and one onWT1 (positions 15 and 16). The first case
also had the mutation katG MUT1 (S315T2) and the second
lacked hybridization only on inhA WT1 (Table 4). On the con-
trary, two susceptible cases showed the absence of both WT- and
MUT-probe hybridization. One strain, susceptible to RIF, lacked
hybridization on theWT7 andMUT2A (H526Y) probes for rpoB.
Another strain lackedWT3,MUT3A (D94A),MUT3B (D94N/Y),
MUT3C (D94G), and MUT3D (D94H) on gyrA and was suscep-
tible to MOX, but the susceptibility profile for CIP is unknown.
DISCUSSION
This study is the first, of which we are aware, to describe the mu-
tations associatedwithM. tuberculosis resistance, both to first- and
second-line antituberculosis drugs, in strains fromColombia.We
TABLE 2 GenoType MTBDRsl performance for second-line antituberculosis drugs
GenoType
MTBDRsl result
Proportion method
results Sensitivitya Specificitya PPVa,b NPVa,c Cohen’s kappaa
Ethambutol (embB) 84.62 (75.01–90.97) 97.1 (90.03–99.2) 97.06 (89.9–99.19) 84.81 (75.3–91.09) 0.810 (0.65–0.97)
Resistant Susceptible
Resistant 66 2
Susceptible 12 67
Ciprofloxacin (gyrA) 88.24 (65.66–96.71) 100 (96.87–100) 100 (79.61–100) 98.35 (94.17–99.55) 0.929 (0.76–1)
Resistant Susceptible
Resistant 15 0
Susceptible 2 119
Moxifloxacin (gyrA) 100 (43.85–100) 88.57 (79.04–94.09) 27.27 (9.746–56.57) 100 (94.17–100) 0.389 (0.20–0.57)
Resistant Susceptible
Resistant 3 8d
Susceptible 0 62
Amikacin (rrs) 93.1 (78.04–98.09) 100 (96.37–100) 100 (87.54–100) 98.08 (93.26–99.47) 0.955 (0.78–1)
Resistant Susceptible
Resistant 27 0
Susceptible 2 102
Kanamycin (rrs) 100 (51.01–100) 100 (82.41–100) 100 (51.01–100) 100 (82.41–100) 1 (0.58–1)
Resistant Susceptible
Resistant 4 0
Susceptible 0 18
a Data are reported as % (95% CI).
b PPV, positive predictive value.
c NPV, negative predictive value.
d Only one strain is a true false positive; the other seven strains are part of the 15 strains that showed resistance to ciprofloxacin due to common gyrA gene-conferred resistance.
TABLE 3Most frequent mutations associated with M. tuberculosis
resistance to first- and second-line drugs
Gene mutation probe
(mutation)
% of strains (no. of mutated strains/no.
of resistant strains detected by GenoType
MTBDRplus and MTBDRsl)
rpoBMUT3 (S531L) 64 (76/119)a
katGMUT1 (S315T1) 88 (110/125)
inhAMUT1 (C15T) 5 (6/125)
gyrAMUT3C (D94G) 87 (13/15)b
rrsMUT1 (A1401G) 96 (27/28)c
embBMUT1B (M306V) 83 (55/66)
a One strain had a double mutation (MUT2A and MUT2B).
b Four strains had multiple mutations: three strains with double mutations (MUT3B
and MUT3C; MUT1 and MUT3C; and MUT3A and MUT3C, respectively) and one
strain with three mutations (MUT1, MUT3A, and MUT3C).
c Twenty-seven strains were resistant to AMK and four to KAN; in this last group, three
of the 27 strains were also resistant to AMK, and one strain was resistant only to KAN.
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performed this evaluation using the GenoType MTBDRplus and
MTBDRsl tests, which are already in use in multiple countries
around the world but were only recently introduced in Colombia.
The majority of the strains evaluated were isolated in the Valle del
Cauca state, where an MDR-TB hot spot was detected previously
(9), in addition to a high proportion of the Beijing genotype
amongMDR-TB cases (10), andwhere 10 out of 14 XDR-TB cases
were detected (11). Information on the performance of these tests
inColombia is valuable, because the use of rapidmolecular tests to
detect resistance to antituberculosis drugs has become an impor-
tant tool in the fight againstMDR-TB and XDR-TB. In Colombia,
the GeneXpert and GenoType tests are used as parts of different
algorithms to detect drug resistance in at-risk populations. Physi-
cians often make therapeutic decisions based first on molecular
test results that are available in days and then submit samples or
cultures for further analysis or confirmation by phenotypic meth-
ods, which usually take weeks. These therapeutic decisions are
cost-effective for health systems, as patients start treatment
quickly and thus there are fewer possibilities for generating or
increasing resistance, which has been correlated with high treat-
ment costs.
In our study, both susceptible and resistant, mainly MDR, M.
tuberculosis strains were evaluated; unfortunately, only a limited
number of strains resistant to second-line drugs were evaluated.
We found the performance of the GenoType tests in Colombia to
be similar to or even better than those described in studies else-
where, like in Mexico, Brazil, Peru, Chile, Bolivia, France, Italy,
Turkey, Spain, Vietnam, the Russian Federation, Ethiopia, and
China (4, 12–23). In general, sensitivity, specificity, positive and
negative predictive values, and concordancewith phenotypicDST
support the utility of these tests for the screening of resistance to
first- and second-line antituberculosis drugs in our country.How-
ever, as somediscordance still exists between the conventional and
molecular approaches to DST, we adhere to the recommendation
that the GenoType tests, particularlyMTBDRplus, should serve as
an early guide for therapy, followed by phenotypic DST confirma-
tion for all cases (24).
The discrepancies found in this studymight be associated with
different factors, such asmutations in alternative genes or changes
in resistance genes that were not detected by the tests. Also, syn-
onymous polymorphisms, or mutations that are not expressed as
a resistant phenotypic profile, are recorded as false-positive cases.
False negatives were found for INH, RIF, EMB, CIP, and AMK.
Alternative resistance genes not included in the tests, such as
ahpC, kasA, and ndh, might explain the occurrence of phenotypic
resistance to INH in the absence of mutations in the tested genes.
Also, mutations not detected in the gyrB gene may be related to
resistance to CIP. For aminoglycosides and cyclic peptides, some
mutations in the rrs, tlyA, eis promoter, and gidB genes have been
associated with resistance (25), and regarding EMB, other genes,
such as embA, embC, and embR, may be important to consider.
Moreover, the absence of WT and MUT probes in the hybridiza-
tion may indicate mutations in positions that are not detected by
theMUT probes. In addition, susceptible strains with nonhybrid-
izing WT probes may suggest the presence of synonymous poly-
morphisms.
The most frequent mutations found in our study were similar
to those reported in other studies in Latin America, Europe, Af-
rica, and Asia, which reveals that several regions share a high fre-
quency of the same mutations, but at the same time, these distri-
butions can vary significantly by country. Specifically, the
frequency of the katGMUT S315T1 in Latin America varied, with
52% in Mexico, 61.9% in Brazil, 71.2% in Peru, and 88% in Co-
lombia (12–14). In comparison, the frequency in some countries
on other continents was 65% in France, 66.5% in Italy, 73% in
Turkey, 87% in Spain, 88% in Vietnam, 94% in the Russian Fed-
eration, and 94% in Ethiopia (17–23).
Likewise, regarding the rpoB geneMUTS531L, the percentages
of the most frequent mutation detected in several Latin America
countries were 47% inMexico. 56.4% in Peru, 56% in Chile, 59%
in Bolivia, and 64% in Colombia (12, 14–16); in other countries
not in the Latin American region, the percentage seems to be
higher, with 47% in France, 53.4% in Turkey, 58.5% in Italy, 60%
in Vietnam, 63% in Spain, 73% in Ethiopia, and 86.9% in the
Russian Federation (17–23).
Studies on the distribution of the mutations related to second-
line anti-TB drugs are limited in Latin America. Some studies in
China, Vietnam, and South Africa revealed that themost frequent
mutations are D94G (gyrA) (36.5%) and A1401G (rrs) (42.1%) in
China, D94G (54%) and A1401G (80%) in Vietnam, and D94G
(42.4%) in South Africa; these were the most frequent mutations
also detected in Colombian strains (4, 21, 26).
This study revealed the presence of heteroresistance, which is
defined as the coexistence of susceptible and resistant microor-
ganisms to antituberculosis drugs in the same patient (27). Alter-
natively, other less-studied molecular mechanisms, such as gene
duplications, may play a role. GenoType tests confirmed their
advantage over phenotypic DST in detecting this, because DST
classifies such strains as susceptible when the patient’s sample ac-
tually has two subpopulations, susceptible and resistant. This rep-
resents a clear advantage of reverse line blot assays. For the time
being, however, it remains unclear what this observation implies
in terms of treatment adjustment and outcomes.
In conclusion, rapid molecular resistance tests to screen for
first- and second-line drug resistance inM. tuberculosis strains in
Colombia were evaluated favorably, given their high concordance
with phenotypic testing and the high predictive value. However, a
newer version of the tests withmoremutations and/ormore genes
might be considered to improve their performance. Further anal-
TABLE 4 Absence of hybridization on wild-type and mutation bands
Gene n
Wild-type probe
(codon[s]) Mutation probe (mutation)
rpoBa 12 WT7 (526–529)b MUT2A (H526Y)-MUT2B (H526D)
2 WT8 (530–533) MUT3 (S531L)
5 WT2/WT3 (510–517) MUT1 (D516V)
2 WT2/WT3 (510–517) and
WT3/WT4 (513–519)
MUT1 (D516V)
inhA 1 WT1 (15–16)c MUT1 (C15T)-MUT2 (A16G)
4 WT2 (8)d MUT3A (T8C)-MUT3B (T8A)
gyrA 1 WT3 (92–97)e MUT3A (D94A)-MUT3B (D94N/Y)
MUT3C (D94G)-MUT3D (D94H)
embB 3 WT1 (306)f MUT1A (M306I)-MUT1B (M306V)
a Strains not associated with additional mutations detected by GenoType in rpoB.
b One of these strains is a false positive. Another strain has double WT probe absence
(WT2/WT3 and WT7).
c Strain with no additional mutations in inhA or katG as detected by GenoType.
d Strains with additional mutations in katG (MUT1/S315T1).
e False positive.
f Strains not associated with additional mutations in embB as detected by GenoType.
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ysis and studies that include sequencing to detect more molecular
targets involved in resistance mechanisms will facilitate this pro-
cess.
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